Nebulized Hypertonic Saline for Inpatient Use in COPD
Chronic Obstructive Pulmonary Disease
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease
Eligibility Criteria
Inclusion Criteria:
- Patients at least 18 years of age
- Admitted to Doctors Hospital with a clinical diagnosis of COPD
- Documented obstruction on spirometry from prior records available at the time of the study.
Exclusion Criteria:
- Patients younger than 18 years of age
- Spirometry data not available
- History of smoking less than twenty pack-years
- Possibility of other primary cause of the patient's change in dyspnea or cough (e.g. pneumonia, congestive heart failure with pulmonary edema, myocardial infarction)
- Patient is found to have a different primary cause after initial enrollment
- Non-English speaking subjects
Sites / Locations
- Doctors Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Hypertonic Saline
Standard Saline
Patients will receive nebulized hypertonic (3%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use). Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale.
Patients will receive standard saline (0.9%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use). Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale.